Abstract
Study Objective: To determine the efficacy and safety of nebulized albuterol in the acute treatment of hyperkalemia in patients on chronic hemodialysis. Design: Prospective, double-blind, and placebo-controlled study. Setting: Outpatient hemodialysis clinic at a university medical center. Patients: Ten patients on maintenance hemodialysis who had chronic hyperkalemia. Interventions: Patients received nebulized albuterol therapy (10 mg or 20 mg) or placebo (saline) on three separate occasions; serial measurements of plasma potassium levels, blood pressure, and pulse were then taken for a 2-hour period. Measurements and Main Results: Patients had a significant decrease in plasma potassium concentrations that was evident by 30 minutes and sustained for at least 2 hours after albuterol treatment. After the administration of 10- and 20-mg doses of albuterol, the maximal decrease in the plasma potassium levels was 0.62 ± 0.09 and 0.98 ± 0.14 mmol/L (SE), respectively. Nebulized saline administration did not produce a significant change in the plasma potassium concentrations. Patients did not develop symptoms or significant changes in blood pressure or heart rate with albuterol treatment. Conclusions: In the doses used, nebulized albuterol therapy resulted in a prompt and significant decrease in the plasma potassium concentrations in patients on hemodialysis, and caused no adverse cardiovascular effects. This treatment should be considered as an important adjunct for acute treatment of serious hyperkalemia in this population of patients.
| Original language | English |
|---|---|
| Pages (from-to) | 426-429 |
| Number of pages | 4 |
| Journal | Annals of Internal Medicine |
| Volume | 110 |
| Issue number | 6 |
| State | Published - 1989 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. / Allon, M.; Dunlay, Robert W.; Copkney, C.
In: Annals of Internal Medicine, Vol. 110, No. 6, 1989, p. 426-429.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nebulized albuterol for acute hyperkalemia in patients on hemodialysis
AU - Allon, M.
AU - Dunlay, Robert W.
AU - Copkney, C.
PY - 1989
Y1 - 1989
N2 - Study Objective: To determine the efficacy and safety of nebulized albuterol in the acute treatment of hyperkalemia in patients on chronic hemodialysis. Design: Prospective, double-blind, and placebo-controlled study. Setting: Outpatient hemodialysis clinic at a university medical center. Patients: Ten patients on maintenance hemodialysis who had chronic hyperkalemia. Interventions: Patients received nebulized albuterol therapy (10 mg or 20 mg) or placebo (saline) on three separate occasions; serial measurements of plasma potassium levels, blood pressure, and pulse were then taken for a 2-hour period. Measurements and Main Results: Patients had a significant decrease in plasma potassium concentrations that was evident by 30 minutes and sustained for at least 2 hours after albuterol treatment. After the administration of 10- and 20-mg doses of albuterol, the maximal decrease in the plasma potassium levels was 0.62 ± 0.09 and 0.98 ± 0.14 mmol/L (SE), respectively. Nebulized saline administration did not produce a significant change in the plasma potassium concentrations. Patients did not develop symptoms or significant changes in blood pressure or heart rate with albuterol treatment. Conclusions: In the doses used, nebulized albuterol therapy resulted in a prompt and significant decrease in the plasma potassium concentrations in patients on hemodialysis, and caused no adverse cardiovascular effects. This treatment should be considered as an important adjunct for acute treatment of serious hyperkalemia in this population of patients.
AB - Study Objective: To determine the efficacy and safety of nebulized albuterol in the acute treatment of hyperkalemia in patients on chronic hemodialysis. Design: Prospective, double-blind, and placebo-controlled study. Setting: Outpatient hemodialysis clinic at a university medical center. Patients: Ten patients on maintenance hemodialysis who had chronic hyperkalemia. Interventions: Patients received nebulized albuterol therapy (10 mg or 20 mg) or placebo (saline) on three separate occasions; serial measurements of plasma potassium levels, blood pressure, and pulse were then taken for a 2-hour period. Measurements and Main Results: Patients had a significant decrease in plasma potassium concentrations that was evident by 30 minutes and sustained for at least 2 hours after albuterol treatment. After the administration of 10- and 20-mg doses of albuterol, the maximal decrease in the plasma potassium levels was 0.62 ± 0.09 and 0.98 ± 0.14 mmol/L (SE), respectively. Nebulized saline administration did not produce a significant change in the plasma potassium concentrations. Patients did not develop symptoms or significant changes in blood pressure or heart rate with albuterol treatment. Conclusions: In the doses used, nebulized albuterol therapy resulted in a prompt and significant decrease in the plasma potassium concentrations in patients on hemodialysis, and caused no adverse cardiovascular effects. This treatment should be considered as an important adjunct for acute treatment of serious hyperkalemia in this population of patients.
UR - http://www.scopus.com/inward/record.url?scp=0024551382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024551382&partnerID=8YFLogxK
M3 - Article
VL - 110
SP - 426
EP - 429
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
SN - 0003-4819
IS - 6
ER -